Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on

P Gorwood1, F Bayle, G Vaiva

  • 1Centre Hospitalier Sainte-Anne (CMME), 100, rue de la Santé, 75014 Paris, France. p.gorwood@ch-sainte-anne.fr

Abstract

Insights

Early assessment of antidepressant response in outpatients can predict treatment success. A two-week evaluation using the QIDS-C scale helps identify effective treatments sooner, avoiding prolonged inadequate therapy.

Area of Science:

  • Psychiatry and Mental Health
  • Clinical Pharmacology
  • Treatment Efficacy Studies

Background:

  • Standard practice suggests delaying antidepressant treatment changes for 4-8 weeks after incomplete response.
  • Early improvement (e.g., 20% symptom decrease by week 2) may predict subsequent treatment success.
  • Limited data exists on early response prediction in non-interventional outpatient studies.

Purpose of the Study:

  • To evaluate the predictive value of early symptom improvement at week 2 for treatment response and remission at week 6 in major depressive disorder outpatients.
  • To identify reliable clinical and self-assessment instruments for predicting antidepressant treatment outcomes.
  • To synthesize evidence from existing studies through meta-analysis regarding early treatment response indicators.

Main Methods:

  • A multicentre, non-interventional study involving 2938 outpatients with major depressive disorder treated with agomelatine.
  • Assessment of mood (QIDS-C, CGI, PGI, VAS), sleep (LSEQ), and functionality (SDS) at baseline, week 2, and week 6.
  • Statistical analysis of week 2 metrics to predict week 6 response/remission, alongside a meta-analysis of 12 prior studies.

Main Results:

  • The QIDS-C (Quick Inventory of Depressive Symptomatology - Self Report) and CGI-I (Clinical Global Impression - Improvement) showed predictive accuracy (Area Under Curve > 0.7).
  • A QIDS-C decrease >5 points strongly predicted treatment response; a CGI-I score >3 indicated a high likelihood of non-response.
  • Meta-analysis confirmed a significant effect size for early improvement as a predictor of treatment outcome.

Conclusions:

  • Findings support the utility of week 2 assessments for predicting antidepressant treatment outcomes in major depressive disorder.
  • Specific cut-offs for QIDS-C and CGI-I at week 2 can enhance prediction accuracy.
  • Combining early assessment data may optimize clinical decision-making regarding treatment adjustments.

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...